Journey Medical (DERM) Cash & Equivalents (2020 - 2026)

Journey Medical's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $27.2 million for Q1 2026.

• Quarterly Cash & Equivalents rose 29.18% year-over-year to $27.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.2 million (up 29.18% YoY) and the FY2025 annual result came in at $24.1 million, up 18.69% from the prior year.
• Cash & Equivalents was $27.2 million for Q1 2026 at Journey Medical, up from $24.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $41.3 million in Q1 2022 and bottomed at $8.2 million in Q2 2023.
• A 5-year average of $26.0 million and a median of $24.7 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 78.4% — and 2024, when it jumped 190.4%.
• Journey Medical's Cash & Equivalents stood at $32.0 million in 2022, then fell by 14.25% to $27.4 million in 2023, then declined by 26.0% to $20.3 million in 2024, then gained by 18.69% to $24.1 million in 2025, then grew by 12.94% to $27.2 million in 2026.
• Business Quant data shows DERM's Cash & Equivalents at $27.2 million in Q1 2026, $24.1 million in Q4 2025, and $24.9 million in Q3 2025.